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ABSTRACT 
Fibrocalculous pancreatic diabetes (FCPD) is an uncommon type of diabetes mellitus, so called tropical diabetes, due to 
chronic calcific non-alcoholic pancreatitis. This type of diabetes is associated to several particularities based on glycemic 
control and the occurrence of degenerative and metabolic complications, in addition to chronic pancreatitis complications such 
us venous thrombosis. We report here a rare case of a young North-African patient with long standing FCPD followed for 25 
years and complicated by portal venous thrombosis. This case presentation highlights how important is to suspect 
fibrocalculous pancreatic diabetes especially in the presence of chronic abdominal pain. The follow-up of such patients should 
be focused not only on the clinical and biological markers of diabetes, but also on pancreatitis complications. 
Keywords: Chronic pancreatitis, Fibrocalculous pancreatic diabetes, North-Africa, Tropical diabetes  
 
oth type 1 and type 2 diabetes mellitus (DM) are 
well known by the physicians and general 
population but other rare forms of DM such as 
Fibrocalculous pancreatic diabetes (FCPD) should be more 
studied. The FCPD is a DM secondary to tropical chronic 
pancreatitis (TCP) which is considered as a form of 
chronic calcific non-alcoholic pancreatitis. This type of 
DM is almost exclusively met in the developing countries 
of the tropical world [1].  
There are little data on the prevalence of FCPD in the 
general population. A study by Balaji et al. [2] found the 
prevalence of TCP to be one in 793 individuals in Kerala. 
In a clinic based study from Chennai, the prevalence of 
FCPD was found to have decreased from 1.6 % (for the 
years 1991–1995) to 0.2 % (during the years 2006–2010) 
[3] .The classical triad of TCP consists of abdominal pain, 
steatorrhoea, and hyperglycemia. 
 
CASE PRESENTATION 
A 17-year-old male, with no familial history of diabetes 
and no alcohol consumption, was hospitalized in 1989 for 
ketone prone diabetes. He has reported abdominal pain for 
about 2 years, in a chronic and relapsing mode associated 
with progressive weight loss. Physical examination has 
revealed body mass index (BMI) of 18.8 kg/m2; waist 
circumference of 85 cm, systolic blood pression of 110 
mmHg and diastolic blood pressure of 80 mmHg. Biologic 
plasma investigation has shown a raised random blood 
glycemia level of 26.7 mmol/l and hemoglobin level of 
14.6 g/dl. The lipid profile, amylase and protidemia levels 
were normal. The urinalysis showed massive glycosuria 
and ketonuria. The abdominal X-ray showed multiple 
pancreatic calcifications (figure 1). Ketosis was well 
managed and the patient has been treated by high doses of 
NPH insulin (1IU/kg/day) to achieve good glycemic 
control. Later, insulin dose degression was scheduled.  
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Figures: Fig. 1 - Abdominal X-ray, performed in 1989, has shown multiple pancreatic calcifications in the pancreatic area. Fig. 2 - 
Contrast Enhanced Computed tomography scan demonstrating complete involution of pancreas (       ) and portal cavernoma (         ) 
and dilatation of main pancreatic duct (        ) 
The 25-year follow-up showed difficulty to obtain a 
good glycemic control despite of a good treatment 
adherence. The patient presented frequent mild 
hypoglycemia (> 2/week), with mild polyuria and nocturia. 
The fasting blood glucose level was always within 10-15 
mmol/l with glycated hemoglobin (HbA1c) within 8.5% - 
11%. Improvement of glycemic control was obtained by 
the use of insulin analogues. No diabetic ketoacidosis has 
occurred during the evolution. Diabetic retinopathy has 
been diagnosed and treated after 10 year-duration of DM. 
In 2009, which corresponds to a 20-year-history of 
DM, the patient presented with abdominal pain and fever. 
Acute pancreatitis with worsening signs of malabsorption 
was documented, including leucocytosis of 21900/mm3; 
anemia of 11.0 g/dl; hypoalbuminemia of 30 g/l and 
hypocholesterolemia of 2.5 mmol/l. Abdominal computed 
tomography (CT) scans revealed chronic calcifiant 
pancreatitis with porto-spleno-mesenteric venous 
thrombosis. No pancreatic tumor was found. The etiologic 
exploration of thrombosis revealed a resistance of 
activated protein C. The patient was treated by pancreatic 
enzyme granules and a lifelong anti coagulation therapy. 
The last biologic control, done in 2013, showed an 
improved glycemic control without any malabsorption 
sign. Abdominal CT showed complete involution of 
pancreas and a portal cavernoma (figure 2). 
DISCUSSION 
We report a 25 years follow-up of FCPD occurred in a 
North-African 17 year-old man and complicated by portal 
thrombosis. FCPD was first reported in 1959 by Zuidema, 
among the lower socioeconomic strata of society [4]. This 
form was included in the World Health Organization 
(WHO) classification in 1980 as tropical diabetes [5]. 
FCPD is secondary to a juvenile form of chronic calcific, 
non-alcoholic pancreatitis, prevalent almost exclusively in 
the developing countries of the tropical world [6]. Several 
studies have debated the theories that malnutrition have 
etiological role in TCP, they confirmed a link between the 
serine protease inhibitor, Kazal type 1 (SPINK 1) gene and 
TCP. It is a vital protease inhibitor that prevents 
unregulated or inappropriate activation of the pancreatic 
enzyme cascade by inhibiting trypsin activity [7-9]. FCPD 
has been classified later by the WHO as a form of diabetes 
secondary to the exocrine pancreas disease (Type 3c 
diabetes mellitus) [10].  
Some of its distinctive features are younger onset, 
presence of large intraductal calculi, accelerated course of 
the disease, and high susceptibility to pancreatic cancer. 
Our patient was first admitted with ketosis-prone diabetes. 
Based on this, as well as young age and a BMI 18.8 kg/m
2
, 
he could be considered as a patient with type 1 DM. 
Unfortunately at that time (1989), anti-pancreatic 
antibodies were not common to assess in our area. 
Nevertheless, our patient presented many additional 
features suggestive of FCPD as reported in the literature, 
such as an onset during youth, rapid progression with bad 
glycemic control on insulin therapy and association to 
pancreatic calcifications without alcohol consumption. 
This type of diabetes is classically known to be difficult to 
achieve a good glycemic control with frequent 
Fig. 1 Fig. 2 Fig. 2 
Cheikhrouhou et al                                         Fibrocalculous Pancreatic Diabetes 
Vol 2 Issue 2 Apr – Jun 2016                                                         Indian J Case Reports / 34 
hypoglycemic episodes, which was the case of our patient. 
Brittle diabetes in patients with FCPD may be explained 
by the loss of pancreatic counter-regulatory hormones i.e. 
somatostatin and glucagon, as well as impaired and 
irregular nutrient absorption due to exocrine pancreatic 
insufficiency. However, this concept remains uncertain.  
A British study on patients with Type 3c DM due to 
pancreatectomy reported a mean HbA1c of 8.1%, which 
was not statistically significant from the entire diabetic 
population (8.2%). None of the patients in this study 
reported a severe hypoglycemic event [11]. No diabetic 
ketoacidosis was noticed in our patient during the 25-year 
follow-up. One of the mechanisms for the ketosis 
resistance seen in FCPD patients was suggested by Mohan 
et al. They demonstrated that there was no significant 
change in plasma glucagon levels in FCPD patients in 
response to an oral glucose load compared with Type 2 
diabetic patients, in whom plasma glucagon levels rose 
after the glucose load [12].  
Our patient presented with retinopathy after 9 years of 
diabetes diagnosis. The occurrence of retinopathy, 
nephropathy [13] and neuropathy [14] in FCPD patients 
was reported in the literature. In a cross sectional 
comparative study, the overall prevalence of these 
complications was not different from a matched group of 
patients with type 2 DM [15]. However, the occurrence of 
cardiovascular events like coronary artery disease and 
peripheral vascular disease is lower among FCPD patients 
and this could be attributed to the lower age and leanness 
of these subjects, as well as to lower lipid levels [7]. Our 
patient has not presented any vascular disease.  
Venous thrombosis is typically reported in cases of 
chronic pancreatitis. It is localized in the splenic vein and 
less commonly in the superior mesenteric vein or portal 
vein [16,19]. Thrombotic complications have been known 
to be more common in alcohol-induced, necrotizing, and 
chronic pancreatitis [17, 18]. We have documented in our 
case a portospleno-mesenteric venous thrombosis 
associated with non-necrotizing and non-alcoholic 
pancreatitis. This complication results from a combination 
of local and systemic prothrombotic risk factors. Local 
factors are mainly stasis, spasm, and mass effects from the 
surrounding inflamed pancreas and direct damage of the 
venous wall by liberated enzymes [16]. Systemic factors 
may be involved such us resistance to activated protein C, 
as confirmed in our patient. Cavernous transformation of 
the portal vein is a sequela of portal vein thrombosis and it 
is the replacement of the normal single channel portal vein 
with numerous tortuous venous channels [17]. This 
process takes a variable amount of time, from as little as a 
week to a year [18,20].  
Although no randomized controlled trial regarding the 
use of anticoagulants in portal vein thrombosis has been 
conducted, the use of unfractionated heparin, with 
subsequent transition to oral anticoagulation, is the most 
common approach. A particular attention is needed for 
patients with pancreatic diabetes to prevent thrombotic 
complications that could be fatal. We suggest clinical 
attention and probably biologic screening for systemic 
disorders of hemostasis for these patients. 
CONCLUSION  
The fibrocalculous pancreatic diabetes remains a rare 
entity which should be suspected in young patient with no 
family history of diabetes or autoimmune predisposition 
and also the occurrence of hypoglycemia with insulin. 
Those patients need a regular monitoring to detect earlier 
multiple complications especially thrombotic 
complications which could be severe and even fatal. 
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